Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.

Dunn SP, Steinhubl SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ.

J Am Heart Assoc. 2013 Jan 15;2(1):e004564. doi: 10.1161/JAHA.112.004564.

2.

Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.

Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E, Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N.

Circulation. 2011 Feb 8;123(5):474-82. doi: 10.1161/CIRCULATIONAHA.110.965640.

3.

Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.

Aihara H, Sato A, Takeyasu N, Nishina H, Hoshi T, Akiyama D, Kakefuda Y, Watabe H, Aonuma K; ICAS Registry Investigators..

Catheter Cardiovasc Interv. 2012 Oct 1;80(4):556-63. doi: 10.1002/ccd.23327.

PMID:
22234956
4.

Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.

Tran M, Tafreshi J, Pai RG.

J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):326-37. doi: 10.1177/1074248410369109. Review.

PMID:
20938037
5.

Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.

Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW.

Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1043-9. doi: 10.1002/pds.2202.

PMID:
21823195
6.

Clopidogrel and proton pump inhibitors--where do we stand in 2012?

Drepper MD, Spahr L, Frossard JL.

World J Gastroenterol. 2012 May 14;18(18):2161-71. doi: 10.3748/wjg.v18.i18.2161. Review.

7.

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD.

Lancet. 2009 Sep 19;374(9694):989-97. doi: 10.1016/S0140-6736(09)61525-7. Review.

PMID:
19726078
8.

Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.

Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP, James SK, Kilhamn J, Steg PG, Harrington RA, Wallentin L; Platelet Inhibition and Patient Outcomes Trial Investigators..

Circulation. 2012 Feb 28;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912.

9.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W.

Arch Cardiovasc Dis. 2013 Oct;106(10):517-27. doi: 10.1016/j.acvd.2013.06.055. Review.

10.

Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.

Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM.

Ann Intern Med. 2010 Mar 16;152(6):337-45. doi: 10.7326/0003-4819-152-6-201003160-00003.

11.

Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention.

Nakayama A, Morita H, Ando J, Fujita H, Ohtsu H, Nagai R.

Heart Vessels. 2013 May;28(3):292-300. doi: 10.1007/s00380-012-0248-3.

PMID:
22460241
12.
13.

Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.

Sarafoff N, Sibbing D, Sonntag U, Ellert J, Schulz S, Byrne RA, Mehilli J, Schömig A, Kastrati A.

Thromb Haemost. 2010 Sep;104(3):626-32. doi: 10.1160/TH09-11-0800.

PMID:
20664905
14.

A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.

Hsiao FY, Tsai YW, Huang WF, Wen YW, Chen PF, Chang PY, Kuo KN.

Clin Ther. 2009 Sep;31(9):2038-47. doi: 10.1016/j.clinthera.2009.09.005.

PMID:
19843493
15.

Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.

Wu CY, Chan FK, Wu MS, Kuo KN, Wang CB, Tsao CR, Lin JT.

Gastroenterology. 2010 Oct;139(4):1165-71. doi: 10.1053/j.gastro.2010.06.067.

PMID:
20600012
16.

[Clinically relevant interaction between clopidogrel and proton pump inhibitors].

Alban S, Dingermann T, Griese N, Kämmerer W, Schubert-Zsilavecz M, Schulz M, Trenk D, Zagermann-Muncke P.

Pharm Unserer Zeit. 2009;38(4):370-1. doi: 10.1002/pauz.200990048. German. No abstract available.

PMID:
19572357
17.

Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.

Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FW, Armstrong PW, White HD, Fox KA, Prabhakaran D, Ohman EM; TRILOGY ACS investigators..

Am Heart J. 2015 Oct;170(4):683-694.e3. doi: 10.1016/j.ahj.2015.05.017.

PMID:
26386792
18.

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.

Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W; Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators..

Stroke. 2004 Feb;35(2):528-32.

19.

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.

Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ; Clopidogrel for the Reduction of Events During Observation Investigators..

Circulation. 2003 Aug 26;108(8):921-4.

20.

Proton pump inhibitor and clopidogrel interaction: fact or fiction?

Laine L, Hennekens C.

Am J Gastroenterol. 2010 Jan;105(1):34-41. doi: 10.1038/ajg.2009.638. Review.

PMID:
19904241
Items per page

Supplemental Content

Support Center